A randomized, open-label, dose-ranging study to evaluate the pharmacokinetics and initial safety of subcutaneous and intramuscular natalizumab in subjects with multiple sclerosis.

Trial Profile

A randomized, open-label, dose-ranging study to evaluate the pharmacokinetics and initial safety of subcutaneous and intramuscular natalizumab in subjects with multiple sclerosis.

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Jun 2015

At a glance

  • Drugs Natalizumab (Primary) ; Natalizumab (Primary) ; Natalizumab (Primary) ; Antineoplastics
  • Indications Multiple sclerosis
  • Focus Pharmacodynamics; Pharmacokinetics
  • Sponsors Biogen Idec
  • Most Recent Events

    • 08 Dec 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 17 Mar 2011 Planned end date changed from 1 Jun 2011 to 1 Nov 2011 as reported by ClinicalTrials.gov.
    • 17 Mar 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top